论文部分内容阅读
目的探讨强化瑞舒伐他汀对老年冠心病患者血清白细胞介素6(IL-6)和超敏C反应蛋白(hs-CRP)以及颈动脉斑块的影响。方法将125例经冠脉造影确诊为冠心病的老年患者随机分成两组,对照组(n=60例)常规每晚口服瑞舒伐他汀10mg,强化组(n=65例)每晚口服瑞舒伐他汀1次,每次20mg,治疗1个月前后测定血清IL-6及hs-CRP,治疗6个月前后用彩色多普勒超声诊断仪检查颈动脉内膜的厚度及颈动脉斑块的变化。结果强化组患者治疗1个月后,血浆中的hs-CRP和IL-6水平显著低于治疗前水平及对照组水平(P<0.01);6个月后,强化组患者双侧颈动脉内膜厚度明显降低及颈动脉斑块面积明显缩小,与治疗前及对照组比较有显著性差异(P<0.01)。结论瑞舒伐他汀有效降低IL-6及hs-CRP的水平,改善老年冠心病患者颈动脉内膜状态,使颈动脉斑块缩小。
Objective To investigate the effects of intensive rosuvastatin on serum interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and carotid plaque in elderly patients with coronary heart disease. Methods A total of 125 elderly patients with coronary heart disease confirmed by coronary angiography were randomly divided into two groups. The control group (n = 60) routinely received 10 mg rosuvastatin per night and the intensive group (n = 65) Shuvastatin 1 times, each 20mg, measured 1 month before and after treatment of serum IL-6 and hs-CRP, 6 months after treatment with color Doppler ultrasound examination carotid artery intima thickness and carotid plaque The change. Results The levels of hs-CRP and IL-6 in the plasma of patients in the intensive group were significantly lower than those of the pre-treatment group and the control group (P <0.01) after one month of treatment. After 6 months, the patients in the intensive group received bilateral carotid artery Significantly decreased membrane thickness and plaque area were significantly reduced (P <0.01) compared with pre-treatment and control groups. Conclusion Rosuvastatin can effectively reduce the levels of IL-6 and hs-CRP, improve the carotid artery intima-mediae of elderly patients with coronary artery disease and narrow the carotid artery plaque.